Medical management of urolithiasis, what oportunity for phytotherapy?

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Atmani, Fouad ^a  

^a FACULTÉ DES SCIENCES   (Morocco)

Author keywords

Calcium oxalate; Drugs; Kidney stones; Nephrolithiasis; Phytotherapy; Review

Indexed keywords

CELLULOSE PHOSPHATE; CHINESE DRUG; CITRATE POTASSIUM; COSTUS SPIRALIS EXTRACT; GLYCOSAMINOGLYCAN; HERBACEOUS AGENT; HERNIARI HIRSUTA EXTRACT; PHYLLANTHUS NIRURI EXTRACT; PLANT EXTRACT; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG;

BANANA; CONCENTRATION RESPONSE; COSTUS; DRUG EFFICACY; EXTRACORPOREAL LITHOTRIPSY; HERNIARI HIRSUTA; HUMAN; HYPERCALCIURIA; KIDNEY FUNCTION; MACROMOLECULE; MAIZE; MEDICINAL PLANT; NEPHROLITHIASIS; PHYLLANTHUS; REVIEW; RICE BRAN; STONE FORMATION; TREATMENT INDICATION; URINE PH; UROLITHIASIS; ANIMAL; PHYTOTHERAPY;

COSTUS; PHYLLANTHUS DEBILIS; PHYLLANTHUS NIRURI; ZEA MAYS;

ANIMALS; HUMANS; PHYTOTHERAPY; URINARY CALCULI;

EID: 4344621660     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1081     Document Type: Review

References (65)

1. Hess B & DJ Kok: Nucleation, growth, and aggregation of stone-forming crystals. In: Kidney stones: Medical and surgical management. Eds: Coe FL, Favus MJ, Pak CYC, Parks JH & GM Preminger. Lippincott-Raven Publishers, PA p 3-32 (1996)
2. Daudon M, Hennequin C, Bader CA, Jungers P, Lacour B & T Drüeke: Inhibitors of crystallization. Adv Nephrol Necker Hosp 24, 167-216 (1995)
3. Daudon M, Bader CA & P Jungers: Urinary calculi: Review of classification methods and correlations with ethiology. Scanning Microsc 7: 1081-1106 (1993)
4. Robertson WG, Peacock M & BEC Nordin: Activity products in stone forming and non stone forming urine. Clin Sci 34: 579-594 (1968)
5. Roberston WG & M Peacock: Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 43: 499-506 (1972)
6. Atmani F, Gokhale JA & SR Khan: Urinary glycoproteins as modulators of calcific nephrolithiasis. In: Urinary System. Jones TC, Hard GC & U Mohr, Springer-Verlag, NY, 438-450 (1998)
7. Fleisch H & Z Bisaz: Isolation from urine of pyrophosphate, calcification inhibitor. Am J Physiol 203, 671-675 (1962)
8. Khan SR: Interactions between stone-forming calcific crystals and macromolecules. Urol Int 59: 59-71 (1997)
9. Atmani F, Lacour B, Jungers P, Drüeke T & M Daudon: Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. Urol Res 22: 257-260 (1994)
10. Foye WO, Hong HS, Kim CM & EL Prien: Degree of sulfatation in mucopolysaccharide sulphates in normal and stone-forming urines. Invest Urol 14: 33-37 (1976)
11. Hess B, Nakagawa Y, Parks JH & FL Coe: Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260: F569-F578 (1991)
12. Borghi L, Meschi T, Amato F, Briganti A, Novarini A & A Giannini: Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5 year randomized prospective study. J Urol 155: 839-843 (1996)
13. Goldfarb S: Diet and nephrolithiasis. Ann Rev Med 45: 235-243 (1994)
14. Bone HG, Zerwekh JE, Britron F & CY Pak: Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards. J Urol 121: 568-571 (1979)
15. Pak CYC, Peterson R, Sakhaee K, Fuller C, Preminger G & J Reisch: Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazid-unresponsive hypercalciuric nephrolithiasis. Am J Med 79: 284-288 (1985)
16. Pak CYC & R Peterson: Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Inter Med 146: 863-867 (1986)
17. Pak CYC & C Fuller: Idiopathic hypocitraturic calcium oxalate nephrolithiasis Successfully treated with potassium citrate. Ann Intern Med 104: 33-37 (1986)
18. Pak CYC, Sakhaee K & C Fuller: Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30: 422-428 (1986)
19. Barcelo P, Wuhl O, Servitge E, Rousaud A & CYC Pak: Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150: 1761-1764 (1993)
20. Slanina P, Frech W, Ekostrom L, Loof L, Slorach S & A Cedergren: Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 32: 539-541 (1986)
21. Molitoris BA, Froment DH, Mackenzie TA, Huffer WH & AC Alfrey: Citrate: A major factor in the toxicity of orally administered aluminum compound. Kidney Int 36: 949-953 (1989)
22. Kohri K, Garside J & NJ Blacklock: The role of magnesium in calcium oxalate urolithiasis. Br J Urol 61: 107-115 (1988)
23. Li MK & Blacklock NJ. Effects of magnesium on calcium oxalate crystallization. J Urol 133: 123-125 (1985)
24. Su CJ, Shevock PN, Khan SR & RL Hackett: Effect of magnesium on calcium oxalate urolithiasis. Br J Urol 145: 1092-1095 (1991)
25. Khan SR, Shevock PN & Hackett RL: Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J Urol 149: 412-416 (1993)
26. Johansson G, Backman U, Danielson BG, Fellstrom B, Ljunghall S & Wikstrom B: Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 124: 770-774 (1980)
27. Melnick I, Landes RR, Hoffman AA & Burch JF: Magnesium therapy for recurring calcium oxalate urinary calculi. J Urol 105: 119-122 (1971)
28. Tiselius HG, Ahlstrand C & Larsson L. Urine composition in patients with urolithiasis during treatment with magnesium oxide. Urol Res 8: 197 (1980)
29. Fetner CD, Barilla DE, Townsend J & Pak CYC: Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 120: 399-401 (1978)
30. Danielson BG: Drugs against kidney stones: Effects of magnesium and alkali. In: Urolithiasis and related clinical research. Schwille PO, Smith LH, Robertson WG & Vahlensieck W, Plenum Press, NY, 549-552 (1985)
31. Norman RW, Scurr DS, Robertson WG & M Peacock: Sodium pentosan as a polyanionic inhibition of calcium oxalate crystallization in vitro and in vivo. Clin Sci 68: 369-371 (1985)
32. Yendt ER, Guay GF & DA Garcia: The use of thiazides in the prevention on renal calculi. Can Med Assoc J 102: 614-620 (1970)
33. Preminger GM & CYC Pak: Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. J Urol 137: 1104-1109 (1987)
34. Hautmann R, Hering FJ & W Lutzeyer: Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long term treatment of absorptive hypercalciuria or hyperoxaluria. J Urol 120: 712-715 (1978)
35. Meyer JL & LH Smith: Growth of calcium oxalate crystals. Invest Urol 13: 36-39 (1975)
36. Zerwekh JE, Holt K & CYC Pak: Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int 23: 838-841 (1983)
37. Kranen MA, Keough D, Gordon RB & BT Emmerson: Xanthine containing calculi during allopurinol therapy. J Urol 133: 658-659 (1985)
38. Ettinger B, Oldroyd NO, Sorgel F & S Darling: Triamterene induced nephrolithiasis. JAMA 244: 2443-2445 (1980)
39. Daudon M & L Estepa: Les lithiases médicamenteuse. Press Med 27: 675-683 (1998)
40. Finlayson B & D Ackerman: Overview of surgical treatment of urolithiasis with special reference to lithotripsy. J Urol 141: 778-779 (1989)
41. Begun FP, Knoll CE, Gottlieb M & RK Lawson: Chronic effects of focused electrohydraulic shock waves on renal function and hypertension. J Urol 145: 635-639 (1991)
42. Kishimoto T, Yamamoto K, Sugimoto T, Yoshihara H & M Maekawa: Side effects of extracorporeal shock-wave exposure in patients treated by extracorporeal shock-wave lithotripsy for upper urinary tract stone. Eur Urol 12: 308-313 (1986)
43. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR & TL Delbanco: Unconventional medicine in the United State. Prevalence, costs, and patterns of use. N Engl J Med 328: 246-252 (1993)
44. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M & RC Kessler: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280: 1569-1575 (1998)
45. Brevoort P: The US botanical market: An overview. HerbalGram 36: 49-57 (1996)
46. Johnston B: One-third of nation's adults use herbal remedies: Market estimated at $3.24 billion. HerbalGram 40: 52 (1997)
47. Akerele O: The WHO traditional medicine program: Policy and implementation: International Traditional Health Newsletter. Geneva, Switzerland, World Health Organization 1: 1 (1985)
48. Farnswoith NR: The role of ethnopharmacology in drug development. In: Bioactive compounds from plants (Ciba Symposium 154) Eds: Chadwick D & J Marsh, NY Wiley (1990)
49. Yokozawa T, N Suzuki, PD Zheng, H Oura & I Nishioka: Effect of orally administered rhubarb extract in rats with chronic renal failure. Chem Pharm Bull 32: 4506-4513 (1984)
50. Zhang G & AM El Nahas: The effect of rhubarb extract on experimental renal fibrosis. Nephrol Dial Transplant 11: 186-190 (1996)
51. Ohkawa T, Ebisuno S, Kitagawa M, Morimoto S & Y Miyazaki: Rice-bran treatment for hypercalciuric patients with urinary calculus disease. J Urol 129: 1009-1011 (1983)
52. Ohkawa T, Ebisuno S, Kitagawa M, Morimoto S, Y Miyazaki & S Yasukawa: Rice-bran treatment for patients with hypercalciuric stones: Experimental and clinical studies. J Urol 132: 1140-1145 (1984)
53. Ebisuno S, Morimoto S, Yoshida T, Fukatani T, Yasukawa S & T Ohkawa: Rice-bran treatment for calcium stone formers with idiopathic hypercalciuria. Br J Urol 58: 592-595 (1986)
54. Grases F, Masarova L, Costa-Bauzá A, March JG, Prieto R & JA Tur: Effect of Rosa Canina infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis. Planta Med 58: 509-512 (1992)
55. Grases F, March JG, Ramis M & A Costa-Bauzá: The influence of Zea Mays on urinary risk factors for kidney stones in rats. Phytotherapy Res 7: 146-149 (1993)
56. Grases F, Ramis M, Costa-Bauzá A, JG March: Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rat. J Ethnopharmacol 45: 211-214 (1995)
57. Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T & K Sugiyama: The inhibitory effect of Kampou extracts on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol 2: 81-86 (1995)
58. Yasui T, Fujita K, Sato M, Sugimoto M, Iguchi M, Nomura S & K Khori: The effect of Takusya, a Kampou medicine, on renal stone formation and osteopontin expression in rat urolithiasis model. Urol Res 27: 194-199 (1999)
59. Calixto JB, Santos ARS, Filho VC & RA Yunes: A review of the genus Phyllantus: Their chemistry, pharmacology, and therapeutic potential. Med Res Ver 18: 225-258 (1998)
60. Freitas AM, Schor N & MA Boim: The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation. BJU Int 89: 829-834 (2002)
61. Santos AR: Analgesic effects of callus culture extracts from selected species of Phyllantus in mice. J Pharm Pharmacol 46: 755-759 (1994)
62. Calixto JB: Antispasmodic effects of an alkaloid extracted from Phyllantus sellowianus: A comparative study with papaverine. Braz J Med Biol 17: 313-321 (1984)
63. Alexander HC & S Nestor: Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells: its role in nephrolithiasis. Nephron 81: 393-397 (1999)
64. Viel TA, Domingos CD, Monteiro AP, Lima-Lanman MTR, Lapa AJ & C Souccar: Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J Ethnopharmacol 66: 193-198 (1999)
65. Atmani F & SR Khan: Effect of an extract from Herniaria hirsuta on calcium oxalate crystallisation in vitro. BJU Int 85: 621-625 (2000)